Dans la plupart des pays, les services de lutte contre la tuberculose (TB) sont décentralisés jusqu’aux dispensaires
les plus périphériques et souvent au sein même des villages et des quartiers. Par contre, les services
de lutte contre le VIH/Sida sont généralement beaucoup plus centralis...és parce que la diffusion des
soins, notamment de la thérapie antirétrovirale (TARV), n’a commencé qu’assez récemment. De ce fait,
les patients qui ont besoin d’un traitement à la fois contre la tuberculose et le VIH/Sida peuvent être obligés
de se rendre dans deux établissements distincts et ainsi d’avoir à parcourir de longues distances pour
accéder aux soins. L’absence de services intégrés TB/VIH peut provoquer des retards dans le diagnostic
et le traitement, et même se traduire par un mauvais suivi des traitements, voire par des interruptions. Par
ailleurs, les patients ont à supporter la charge financière des frais de déplacement et des autres coûts indirects,
tels que de longs temps d’attente et une perte de revenu
more
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
This interactive website provides detailed information on current and past BCG policies and practices for over 180 countries. The Atlas is designed to be a useful resource for clinicians, policymakers and researchers alike, providing information that may be helpful for better interpretation of TB di...agnostics as well as design of new TB vaccines
more
This strategic framework marries formerly separate mandates for HIV and TB management in to one, comprehensive collaboration. It provides a structure for how to: strengthen the health care system to respond effectively to both epidemics, reduce the burden of HIV/AIDS in TB patients, and establish a ...monitoring and evaluation system for the collaborative activities. Activities include: improving TB infection control in health care and other settings, enhancing TB/HIV diagnostic capacity, and harmonize data collection tools and local, national and international TB/HIV indicators.
more
The modules (1-12) are based on materials originally developed by FIND, KNCV and Cepheid, and are in PowerPoint format for country customization. Depending on the audience, modules may be selected and adapted according to need (e.g. basic users, supervisors, clinicians). Topics covered include: Over...view of TB and diagnostics, biosafety, specimen collection, procurement, installation, Xpert MTB/RIF technology, results interpretation, reporting, troubleshooting, maintenance, a clinical guide, and quality assurance.
Please download each manual directliy from the website
more
Information note.
This information note provides a strategic overview of key implementation considerations for diagnostic integration using these devices, and is primarily intended for use by national laboratory services and TB, HIV, and hepatitis programme managers.
It may also be of inte...rest to managers of maternal, newborn and child health programmes and sexual and reproductive health programmes, international and bilateral agencies, and organizations that provide financial and technical support to the relevant national health programmes.
more
Given the current situation of the COVID-19 pandemic, countries are advised to continue adopting the TB diagnostic algorithms recommended by PAHO / WHO.
Despite the differences in the modes of transmission of TB and COVID-19, certain personal protection measures are relevant for both diseases. Rout...ine measures to protect yourself from TB should continue along with additional precautions to protect workers from COVID-19.
more
Dada a atual situação da pandemia da COVID-19, os países são orientados a continuar a adotar os algoritmos diagnósticos para tuberculose (TB) recomendados pela OPAS/OMS. Apesar das diferenças nos modos de transmissão da TB e do vírus responsável pela COVID-19, certas medidas de proteção p...essoal são relevantes para ambas as doenças. As medidas de rotina para a proteção contra a TB devem continuar, juntamente com precauções adicionais para proteger os trabalhadores contra a COVID-19.
more
Meeting Report 27-29 October 2020
The overall goal of the meeting was to discuss recent changes in treatment regimens and diagnostics for drug-resistant TB and to determine how these impact on the definition of XDR-TB, with a view to revising this definition. The pre-existing definition of XDR-TB w...as formulated in 2006 at a meeting of the Global Taskforce on XDR-TB, convened by WHO, and has been in use for clinical and surveillance purposes, since this time.
more
This Rapid Communication aims to inform national TB programmes and other stakeholders about the key implications of the latest evidence on the use of specific molecular assays as initial diagnostic tests of pulmonary and extrapulmonary TB and RR-TB, in adults and children.
Este documento presente es para brindar lineamientos al personal del Sistema Nacional Integrado de Salud que atiende casos o personas con sospecha de TB durante el período de emergencia por el COVID-19. Incluye directrices de la distribución del medicamento antifimico a los establecimientos de sa...lud, así como el seguimiento, con el fin de evitar la exposición de los casos diagnosticados de COVID-19. Finalmente brinda consejería y de medidas de protección a todos las personas con TB, para evitar el contagio de COVID-19.
more
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij...ing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection. Full details are provided in this WHO policy statement.
more
This course will provide you with the knowledge and skills needed to implement WHO-recommended TB tests and algorithms. It includes the latest recommendations for novel tests for TB diagnosis and detection of drug resistance, as well as the most recent WHO policy guidance for the use of those tests.... The course also describes the processes and steps for implementing a new diagnostic test for routine use within the TB diagnostic network
more
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama...nid in young children with multidrug- and rifampicin-resistant TB and decentralized and family-centred, integrated models of care for TB case detection and prevention in children and adolescents.
more
Este documento presenta modelos de algoritmos que permiten investigar por métodos bacteriológicos a los pacientes para el diagnóstico de tuberculosis (TB), TB asociada al Virus de Inmunodeficiencia Humana (TB-HIV) y TB drogorresistente (TBDR).
Technical information note. Ensuring an uninterrupted supply of quality-assured, affordable anti-TB
drugs and diagnostics to the world
A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to
Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa to an increase in virulence towards the north. However, only limited d...ata on the clinical presentation of T.b. rhodesiense HAT is available. From 2006-2009 we conducted the first clinical trial program (I MPAMEL III) in T.b. rhodesiense endemic areas of
Tanzania and Uganda in accordance with international standards (ICH-GCP). The primary and secondary outcome measures were safety and efficacy of an abridged melarsoprol schedule for treatment of second stage disease. Based on diagnostic findings and clinical examinations at baseline we describe the clinical presentation of T.b. rhodesiense HAT in second stage patients from two distinct geographical settings in East Africa.
more
FIND and Standard Diagnostics (SD) have developed a lateral flow rapid diagnostic test (RDT) to screen for
T.b. gambiense HAT that is cheap and easy to use. The tests are packed individually and are stable at 40°C for
up to 25 months; they are performed on fresh blood obtained from a finger prick..., and no instrument or electricity is required. The RDT detects host antibodies to infection in populations that are at risk, or in suspect individuals. Positive cases are subjected to further confirmatory methods to identify HAT patients.
more
This analysis focused on the chronic form of HAT caused by T. b. gambiense, as it contributes to the majority of disease burden. Information from the literature review,
product development landscape, and stakeholder interviews was compiled to:
- Identify use cases and understand current diagnosti...c practices and tools associated with each use case.
- Analyze progress toward robust diagnostics for HAT across different biomarkers.
- Develop recommendations for steps to improve the availability, access, and adoption of HAT diagnostic tools.
more
En la reunión de alto nivel de las Naciones Unidas del 2018 se fijó el objetivo de tratar al menos a 40 millones de personas con tuberculosis (TB) entre el 2018 y el 2022; sin embargo, en el 2021 ese objetivo solo se había cumplido en un 66%. Las pruebas diagnósticas son fundamentales para logra...r el objetivo, pero constituyen un eslabón débil en la continuidad de la atención. Las pruebas de diagnóstico rápido recomendadas por la Organización Mundial de la Salud (PDRO) son sumamente precisas, acortan el tiempo hasta el inicio del tratamiento, influyen en resultados importantes para el paciente y son costo-eficaces. Aunque el objetivo para el año 2025 es que todos los pacientes notificados se hagan inicialmente una PDRO, en el 2021 tan solo el 38% se hizo una PDRO como prueba inicial, y se determinó que el acceso a las pruebas diagnósticas era un problema crítico. Una de las principales consecuencias del uso insuficiente de las PDRO es la gran brecha en la detección de la farmacorresistencia. La presente Norma de la OMS: Acceso universal a las pruebas de diagnóstico rápido de la tuberculosis se basa en las directrices de la OMS y en el manual operativo conexo
more